ClinicalTrials.gg
Sign In
Drug

Enzalutamide clinical trials

Also written Xtandi, MDV3100 and ASP9785.

studies test it
176
open now
25
in phase 3
23
first study started
2005

How each study uses enzalutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the enzalutamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
31 Aug 2012 · XTANDI · NDA 203415 (FDA, Drugs@FDA)
European Union
21 Jun 2013 · Xtandi · EMEA/H/C/002639 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Enzalutamide
151
Enzalutamide capsule
2
selective androgen receptor modulator MDV3100
2
Enzalutamide 40 MG
2

Brand

Xtandi
117

Development codes

MDV3100
76
ASP9785
29
HC-1119
6

Studies by the year they started

176 studies that test it; most in 2014 (25)

Studies that test enzalutamide, by start year
YearStudies
20051
20071
20091
20103
20118
20128
201314
201425
201521
201615
201716
20186
201913
202012
20215
20227
20234
20249
20253
20264

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
50
Phase 2
107
Phase 3
23
Phase 4
9
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Prostatic Neoplasms
87
Breast Neoplasms
10
Neoplasms
6
Prostatic Neoplasms, Castration-Resistant
5
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
1
Seizures
1
Pancreatic Neoplasms
1
Carcinoma, Hepatocellular
1

Who runs them

Industry 69 · Other 107

Pfizer (16) · Astellas Pharma Global Development, Inc. (11) · Astellas Pharma Europe B.V. (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Astellas Pharma Inc (7) · Memorial Sloan Kettering Cancer Center (5) · National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (4)

Often tested with

Tested in the same studies.

Abiraterone (18) · Abiraterone Acetate (13) · Docetaxel (8) · Cabazitaxel (5) · Darolutamide (5) · Apalutamide (5) · Leuprolide (4) · Paclitaxel (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 9 phase 3 studies under way

Enzalutamide is the comparator. A study of two new drugs counts under both.

  • 2Atezolizumab · Hoffmann-La Roche, Exelixis · next primary completion Jul 2028
  • 2Cabozantinib · Hoffmann-La Roche, Exelixis · next primary completion Jul 2028
  • 2Opevesostat · Merck Sharp & Dohme LLC · next primary completion May 2028
  • 1Niraparib · Hoffmann-La Roche · next primary completion Jul 2028
  • 1Dezandrodeg · Celgene · next primary completion Sep 2027
  • 1Xaluritamig · Amgen · next primary completion Jan 2029
  • 1Darolutamide · ECOG-ACRIN Cancer Research Group · next primary completion Mar 2029
  • 1Risvutatug rezetecan · GlaxoSmithKline · next primary completion Dec 2029
Reaching primary completion within a year · 16, 3 in phase 3

Studies that test enzalutamide, phase 3 first.

Studies

Open first, then newest update. How each study uses enzalutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 176

See all 176 studies that test enzalutamide →

Given beside what is tested · 110 — enzalutamide is usual care or a partner of the new treatment

Showing 20 of 110.

As the comparator · 25 — what is tested is compared with enzalutamide

Showing 20 of 25.

Codes

What other systems call enzalutamide · ClinicalTrials.gg INT005424

  • MeSH (NLM) C540278enzalutamideConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 93T0T9GKNUENZALUTAMIDEConfirmed FDA, NLM, Wikidata
  • RxNorm 1307298Confirmed FDA, Wikidata
  • Wikidata Q1996756enzalutamideConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C71744EnzalutamideOne source FDA
  • DrugBank DB08899One source Wikidata

Also registered as deutenzalutamide (UNII 3OKI556HC2).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.